TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00990691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of a placebo
Description: Administration of a daily dose of placebo
Study: NCT00313820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
Study: NCT03543254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A
Description: 90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures.
Study: NCT00988312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous idiotype-protein pulsed dendritic cells
Description: Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous idiotype-protein pulsed dendritic cells
Description: Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
Study: NCT05257096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical clown
Description: The medical clown will meet the children in the waiting room for 15-30 minutes and will accompany them through the whole investigation, up to one hour.
Study: NCT01295554

Intervention type: OTHER
Intervention: NCE MRA and CE MRA
Description: Each patient will receive on the same day:~* NCE MRA~* CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images.
Study: NCT01764737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: single dose intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose intravenous administration
Study: NCT01711203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control
Description: Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Strengthening
Description: General abdominal and lower quarter musculature strengthening
Study: NCT03221387

Intervention type: DEVICE
Group type: OTHER
Intervention: Humidified nasal high flow with oxygen
Description: The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
Study: NCT03852875

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Same
Study: NCT04673071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thread Embedding Acupuncture (TEA)
Description: TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-TEA (STEA)
Description: STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
Study: NCT02042170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human growth hormone self-injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human growth hormone self-injection
Study: NCT01053182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ivor-Lewis Esophagectomy
Description: Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sweet Esophagectomy
Description: Esophagectomy through Left Side Thoracotomy
Study: NCT02085252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide tablets
Study: NCT01521676

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: molecular alteration
Description: research of molecular alteration
Study: NCT00059358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin plus interferon alfa-2b
Description: Oral tablets taken daily
Study: NCT02042170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human growth hormone self-injection
Study: NCT00059358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral tablet taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Subcutaneous injection
Study: NCT03511755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Electrical Neuromodulator (TEN)
Description: Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Electrical Neuromodulator (TEN)
Description: Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
Study: NCT01109602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga focused on strength, flexibility, and balance
Description: Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga focused on strength, flexibility, and balance
Description: Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
Study: NCT01190228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JE-CV Vaccine
Description: 0.5 mL (single dose), Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JE-CV Vaccine
Description: 0.5 mL (single dose), Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Vaccine
Description: 0.5 mL (single dose), Subcutaneous
Study: NCT03502382

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: x-ray
Description: Radiological: standing antero-posterior full-length digital images of the lower extremities
Study: NCT01464541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operative fracture size vs CT fracture size
Description: comparing actual intraoperative fracture size to the CT fracture size

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orbital fracture intraoperative measurement
Description: comparing intraoperative fracture size to the CT orbital fracture size
Study: NCT01826474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO045, 0.15 mg/kg/week
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO045, 1.0 mg/kg/week
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO045, 3.0 mg/kg/week
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO045, 6.0 mg/kg/week
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO045, 9.0 mg/kg/week
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO045, selected dose
Description: Subcutaneous injection
Study: NCT01905020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
Study: NCT00748462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 Laser
Description: the treatment settings:~1. Pulse duration : 5 to 7ms depending on skin reaction~2. Spot Density: 49 MTZ/cm2 (Low density)~3. Power: 15 W = (75 - 105) mJ/MTZ
Study: NCT03200769

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP active
Description: CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP active
Description: CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP placebo
Description: CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.
Study: NCT01799512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental: real-time continuous glucose monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: blinded continuous glucose monitoring
Study: NCT04284098

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia (GA).
Description: Patients received standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block using bupivacaine .
Description: The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%, after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block using bupivacaine and dexmedetomidine
Description: D group:The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%+dexmedetomidine (1µg/kg) after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
Study: NCT03533712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified balanced energy-protein (BEP) supplement
Description: The product contains the following target nutrients:~* Total energy: 250-500 kcal per daily serving~* Fat content: 10-60% of energy intake~* Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~* Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~* Trans Fats: \<1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fe and folic acid supplement
Description: Routine iron and folic acid supplementation.
Study: NCT01643590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100 15 mg dose Injection
Description: Intramyocardial Injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Intramyocardial Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100 30 mg dose injection
Description: Intramyocardial Injection
Study: NCT03565029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Capecitabine and Oxaliplatin (4x cycles)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Pelvic radiotherapy
Study: NCT00447343

Intervention type: PROCEDURE
Intervention: Decompressive cervical spine surgery
Description: Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery~Healthy volunteers will ONLY undergo two scans 6 months apart.

Intervention type: PROCEDURE
Intervention: fMRI and MRS scan
Description: A scan pre-op and 6 months post-op.
Study: NCT04625712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Cholecystectomy within the first week after a mild acute biliary pancreatitis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Cholecystectomy within the first week after a mild acute biliary pancreatitis
Study: NCT01461876

Intervention type: DRUG
Intervention: antiretroviral therapy
Description: Standard of care antiretroviral therapy
Study: NCT01959724

Intervention type: OTHER
Group type: OTHER
Intervention: Vitrectomy
Study: NCT04398277

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Coping Toolkit
Description: 1. Emotion Labelling Activity: Participants rate 10 discrete negative and positive emotional words on a likert scale (0-4).~2. Expressive Writing and Self Distancing Activity: Participants respond to an open-ended prompt to write about their day in an open text box in response to the prompt: What was today like for you? After this is completed, they are prompted that if the experience was very challenging, to revisit that experience in their mind by taking a fly on the wall perspective (Kross \& Ayduk, 2016).~3. Positive Emotion Generation Activity (1 v. 2 prompts) Participants are prompted to take a deep breath and then respond to 1 (or 2) of 8 possible prompts in which they can generate positive emotions. In response to each, they are asked to describe their thoughts or memories in open-ended text box.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Coping Toolkit
Description: 1. Emotion Labelling Activity: Participants rate 10 discrete negative and positive emotional words on a likert scale (0-4).~2. Expressive Writing and Self Distancing Activity: Participants respond to an open-ended prompt to write about their day in an open text box in response to the prompt: What was today like for you? After this is completed, they are prompted that if the experience was very challenging, to revisit that experience in their mind by taking a fly on the wall perspective (Kross \& Ayduk, 2016).~3. Positive Emotion Generation Activity (1 v. 2 prompts) Participants are prompted to take a deep breath and then respond to 1 (or 2) of 8 possible prompts in which they can generate positive emotions. In response to each, they are asked to describe their thoughts or memories in open-ended text box.
Study: NCT00677365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376
Description: 3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376
Description: 3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376
Description: 3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
Study: NCT00447343

Intervention type: PROCEDURE
Intervention: fMRI and MRS scan
Description: A scan pre-op and 6 months post-op.
Study: NCT00677365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same frequency as study drug using the same nebulizer
Study: NCT04249622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care pertuzumab-based chemotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care pertuzumab-based chemotherapy
Study: NCT02786875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low Glycemic Index Mediterranean diet
Description: All carbohydrate foods will be low GI choices (GI\<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Description: Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic physical activity
Description: General recommendations for physical activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high level Vitamin D
Description: Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
Study: NCT04249622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Given PO
Study: NCT02786875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal level Vitamin D
Description: Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
Study: NCT01774149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Few Touch Application
Description: Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Few Touch Application
Description: Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diastat
Description: Users get the Few Touch Application with Diastat module activated.
Study: NCT00280280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular Botox versus oral baclofen
Description: Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
Study: NCT01774149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diastat
Description: Users get the Few Touch Application with Diastat module activated.
Study: NCT02225860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and water adjustment
Description: The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
Study: NCT00863174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC147709
Description: SPARC147709 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference147709
Description: Reference147709 injection